Ramesh Ramalingam
☆    

India,
2018-10-18 09:16
(1988 d 14:17 ago)

Posting: # 19463
Views: 2,126
 

 Theophylline ER 450 mg study design [Design Issues]

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.


Regards,
Ramesh
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
63 visitors (0 registered, 63 guests [including 5 identified bots]).
Forum time: 22:34 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5